Global pharmaceutical company UCB has launched a major new informatics initiative that will make use of Genedata’s Expressionist and Phylosopher platforms. The software will be used to help discover drugs for central nervous system disorders, allergies and respiratory diseases, immune disorders and oncology.
The Expressionist platform is ideal for biomarker discovery, and provides a single interface for scientists to access public and private data. Used in conjunction with Phylosopher, it will optimise the analysis and storage of UCB’s microarray data, providing even deeper insights into the biology of the systems being studied.
Dr Phil Scordis, UCB senior group leader for informatics explained: ‘Phylosopher will enable us to integrate proprietary data with relevant information from the public domain, and aid the interpretation of our experimental data.’
Genedata’s products were also chosen because they could be integrated with UCB’s existing databases and client servers.
